In this context, Li and colleagues have demonstrated that ADO is generated by the classical CD39/CD73 adenosinergic pathway, and that ovarian cancer patients treated with metformin display an increased anti-tumor activity paralleled by a reduction of circulating CD39+/CD73+ MDSCs [60]. Here, ENTPD1 is linked to ovarian cancer.